Aseptic Processing: A Primer - NIBRT's Ray O'Connor provides an overview of aseptic processing. - BioPharm International

ADVERTISEMENT

Aseptic Processing: A Primer
NIBRT's Ray O'Connor provides an overview of aseptic processing.

BioPharm International
Volume 26, Issue 1, pp. 52-55

PRODUCT CONTAMINATION

BioPharm: What types of product contamination can occur during bioprocessing?

O'Connor: Contamination in the biopharmaceutical industry can have serious health effects on the patient, so it is crucial to monitor and avoid. The different types of contamination one might find include bacteria, which could cause an infection in someone who is already ill, thus making the actual condition worse; chemicals, which could cause poisoning or other effects on the patient; and physical contamination, which could be particulates that can cause serious problems, such as cuts, blockage, or even death in the patient. If work is being done in a multiproduct facility, cross-contamination from one product to another can occur as well.

With regard to bacteria, viable particles are of particular concern in the biopharmaceutical industry. If they enter a product, they will multiply rapidly (e.g., they can double in under 20 minutes in the right conditions). If bacteria get into the system, they can actually overpower the product being made, and you may end up losing the product.

Most bacterial contamination comes from human beings. Hence, it's vitally important that, when staff walk into a cleanroom or work in a cleanroom, they be appropriately garbed to ensure minimal exposure of skin to the environment.

Overall, there are five main routes of entry into the product of any type of contaminant. First is raw materials. All the raw materials used in the manufacturing of the product are potential sources of contamination. Quality systems associated with the supply and release of raw materials into the manufacturing processes are critical. A second source is the plant. Poorly sanitized equipment can lead to contamination. A third source is the environment. The cleanroom design, as described below, must be executed properly. Fourth is movement of personnel. It's important that people move in a controlled and deliberate fashion in a cleanroom. Erratic behavior can generate particles. A fifth source is gowning. People represent 80 to 90% of common contamination sources. Proper gowning behavior and training in aseptic technique and aseptic processing is vital.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here